


RealRate

## PHARMACEUTICAL 2021



## Altimmune Inc. Rank 96 of 409





RealRate

## PHARMACEUTICAL 2021



## Altimmune Inc. Rank 96 of 409

The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 174% points. The greatest weakness of Altimmune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 392% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	230,257
Cost of Goods Sold	0
Intangible Assets	12,824
Liabilities, Current	12,020
Liabilities, Non-Current	0
Other Assets	977
Other Compr. Net Income	-24
Other Expenses	-5,417
Other Liabilities	7,218
Other Net Income	337
Property and Equipment	1,057
Research and Development	49,774
Revenues	8,185
Selling, General and Administrative Expense	13,209

Output Variable	Value in 1000 USD
Assets	245,115
Liabilities	19,239
Expenses	57,567
Stockholders Equity	225,876
Net Income	-49,044
Comprehensive Net Income	-49,057
Economic Capital Ratio	37%